Clinical investigation of the biopharmaceutical characteristics of nifurtimox tablets - Implications for quality control and application.
第一作者:
Heino,Stass
第一单位:
Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany. Electronic address: heino.stass@bayer.com.
作者:
医学主题词
投药, 口服(Administration, Oral);成年人(Adult);曲线下面积(Area Under Curve);生物利用度(Biological Availability);生物制品(Biological Products);儿童(Child);儿童, 学龄前(Child, Preschool);交叉研究(Cross-Over Studies);禁食(Fasting);人类(Humans);硝呋替莫(Nifurtimox);质量控制(Quality Control);片剂(Tablets);治疗等效(Therapeutic Equivalency)
DOI
10.1016/j.ejps.2021.105940
PMID
34265407
发布时间
2021-09-15
- 浏览1
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



